NCT01625559View on ClinicalTrials.gov

Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Stargardt's Macular Dystrophy
Interventions
BIOLOGICAL

MA09-hRPE

MA09-hRPE cells

Trial Locations (1)

463-712

CHA Bundang Medical Center, Seongnam-si

All Listed Sponsors
lead

CHABiotech CO., Ltd

INDUSTRY

NCT01625559 - Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD) | Biotech Hunter | Biotech Hunter